Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

31.0K
Overview
31.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.

Neurology·2026
Same author

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Annals of neurology·2026
Same author

Simple against advanced imaging for the selection of stroke therapy in the extended window (VESTA study).

European stroke journal·2026
Same author

Tear CHI3L1 in multiple sclerosis: a non-invasive biomarker linked to disease progression.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: Jun 5, 2025

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

756

Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.

Manuel Comabella1,2, Harald Hegen3, Luisa M Villar4

  • 1Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Journal of Neurology
|December 12, 2024
PubMed
Summary
This summary is machine-generated.

Primary progressive multiple sclerosis (PPMS) patients show heightened immune responses to Epstein-Barr virus nuclear antigen 1 (EBNA1). Chronic cytomegalovirus (CMV) infection may also be linked to progressive MS.

Keywords:
Epstein–Barr virusHuman cytomegalovirusMultiple sclerosisPrimary progressiveVirus

More Related Videos

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

7.0K
Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

10.9K

Related Experiment Videos

Last Updated: Jun 5, 2025

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

756
Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

7.0K
Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

10.9K

Area of Science:

  • Neuroimmunology
  • Virology
  • Multiple Sclerosis Research

Background:

  • Viral infections' impact on multiple sclerosis (MS) susceptibility and progression is primarily studied in relapse-onset MS (RMS).
  • Limited research exists on immune responses to common viruses in primary progressive MS (PPMS).
  • Understanding these responses in PPMS is crucial for disease management and therapeutic strategies.

Purpose of the Study:

  • To investigate immune responses to ubiquitous viruses in patients with PPMS.
  • To compare viral antibody levels in PPMS patients with healthy controls.
  • To explore potential correlations between antiviral immunity and disease progression in PPMS.

Main Methods:

  • Antibody responses to Epstein-Barr virus (EBV) (EBNA1, VCA), human herpesvirus 6 (HHV-6), human cytomegalovirus (HCMV), and measles virus were measured.
  • A cohort of 68 PPMS patients with an 8-year follow-up was compared to 66 age- and sex-matched healthy controls.
  • Seroprevalence rates and specific antibody titers were analyzed.

Main Results:

  • PPMS patients exhibited significantly increased humoral immune responses to the latent EBV-encoded nuclear antigen-1 (EBNA1) compared to controls.
  • No significant differences were found in responses to lytic EBV capsid antigen (VCA) or other tested viral antigens (HHV-6, measles).
  • Seroprevalence rates for human cytomegalovirus (HCMV) were notably higher in the PPMS cohort. Baseline antiviral immune responses did not correlate with disability progression.

Conclusions:

  • Elevated immune responses targeting EBNA1 are selectively increased in PPMS, suggesting a role in both RMS and PPMS pathogenesis.
  • Chronic HCMV infection is associated with progressive MS, warranting further investigation.
  • These findings highlight specific viral-associated immune dysregulation in progressive MS.